ArticleHaematologica2011
Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.
Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Role of Dicer as a prognostic predictor for survival in cancer patients: a systematic review with a meta-analysis.Oncotarget · 2016Pooled it
- Possible role of human ribonuclease dicer in the regulation of R loops.FEBS open bio · 2025Review
- Evaluation of the clinical significance of RNase III enzyme DROSHA in pediatrics acute lymphocytic leukemia.Molecular biology reports · 2021Article
- Epigenetic Aberrations in Multiple Myeloma.Cancers · 2020Review
- Review
- Factors Regulating microRNA Expression and Function in Multiple Myeloma.Non-coding RNA · 2019Review
- MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN.Cancer biomarkers : section A of Disease markers · 2019Article
- Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.Journal of hematology & oncology · 2017Review
- MicroRNAs in multiple myeloma and related bone disease.Annals of translational medicine · 2015Review
- miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.Oncotarget · 2015Article
- Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.The Journal of molecular diagnostics : JMD · 2015Article
- Review
- Clinicopathological and prognostic significance of the microRNA processing enzyme DICER1 mRNA expression in colorectal cancer patients.Molecular and clinical oncology · 2013Article
- MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.ISRN hematology · 2013Article
- Promises and challenges of MicroRNA-based treatment of multiple myeloma.Current cancer drug targets · 2012Review
- Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia.Cancer science · 2012Article
- MicroRNAs: New Players in Multiple Myeloma.Frontiers in genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dicer and Drosha are key enzymes in the miRNA-processing pathway which is altered in many human cancers. We analyzed Dicer and Drosha expression levels by quantitative PCR in 151 patients with monoclonal gammopathies: 102 symptomatic myeloma patients, 23 smoldering myelomas and 26 monoclonal gammopathy of undetermined significance. We found that Dicer expression values were significantly higher in monoclonal gammopathy of undetermined significance than in smoldering myelomas and symptomatic myeloma (mean ± SD, 0.84 ± 0.36 vs. 0.60 ± 0.23 and 0.62 ± 0.51; P<0.01). Moreover, the median progression-free survival was significantly longer in symptomatic myeloma patients with high expression of Dicer (not reached vs. 23.6 months; P=0.02). By contrast, no differences in the expression of Drosha among these groups of patients were observed. Our data suggest that Dicer expression may play an important role in the progression and prognosis of monoclonal gammopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.